Welcome to our dedicated page for Inotiv SEC filings (Ticker: NOTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inotiv, Inc. (NASDAQ: NOTV) SEC filings page on Stock Titan provides centralized access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-assisted summaries to help interpret key points. Inotiv is a contract research organization offering nonclinical and analytical drug discovery and development services and research models and related products and services, and its filings offer detailed insight into how this business operates and evolves.
Through periodic and current reports, investors can review how Inotiv reports performance in its Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments, including revenue drivers such as safety assessment services, general toxicology, biotherapeutic analysis, discovery and translational sciences services, and non-human primate product and service revenues. Annual and quarterly reports (such as Forms 10-K and 10-Q, when available) typically include segment discussions, risk factors, liquidity and capital resources, and descriptions of non-GAAP measures like Adjusted EBITDA that the company uses to evaluate its operations.
Current reports on Form 8-K, several of which are reflected in the recent data, highlight material events such as preliminary financial results, corrections to earnings releases, cybersecurity incidents, and legal and regulatory developments. Examples include disclosures about a cybersecurity incident affecting certain systems and data, proposed settlements of securities class action and derivative litigation, updates on investigations related to non-human primate importations, and engagement of financial advisors to explore potential debt refinancing alternatives.
Stock Titan’s interface is designed to surface these filings in real time as they are posted to EDGAR, while AI-generated explanations can help clarify complex sections, such as litigation descriptions, settlement terms, governance commitments, and capital structure updates. Users can also review insider and executive-related filings, such as Forms 3, 4, and 5 when available, to understand equity transactions by officers and directors.
By using the NOTV SEC filings page, investors and researchers can quickly locate Inotiv’s official regulatory communications and rely on AI tools to interpret how reported financial results, risk disclosures, legal matters, and strategic initiatives relate to the company’s nonclinical and research model-focused business.
Inotiv President and CEO Robert Leasure Jr. had 113,297 shares of common stock automatically sold on February 2, 2026 at a weighted average price of $0.5034 per share to satisfy tax withholding obligations on vested restricted stock units.
Following this sell-to-cover transaction, he directly beneficially owned 1,273,025 common shares. An additional 105,000 shares are held by an entity for which he is the majority security holder, and he disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.
A holder of NOTV common stock has filed a notice of proposed sale under Rule 144. The filer plans to sell 120,000 shares through Raymond James & Associates on or about 02/02/2026 on the NASDAQ market, with an aggregate market value of $59,088.00. The issuer had 34,400,000 shares outstanding. The securities to be sold are part of a 300,000-share RSU grant of common stock acquired on 02/01/2026, with cash payment dated 02/02/2026.
Inotiv, Inc. files an amended annual report to add detailed Part III information on directors, executive compensation, ownership and auditor fees, without revising previously reported financial results. The filing describes a largely independent board with a separate, independent chair and CEO roles.
For fiscal 2025, executives received base salary increases and significant stock-based incentives, but no annual cash bonuses were paid despite approved bonus targets. CEO total compensation was $2,941,549, and the CEO pay ratio was 50:1 versus a median employee at $58,998. Directors and executives as a group beneficially owned about 10.7% of common shares.
Inotiv, Inc. reported that a federal court has issued a preliminary approval order for a proposed settlement of consolidated stockholder derivative actions in federal and Indiana state court. Under the proposed settlement, the company will implement certain corporate governance measures and receive a $2,490,000 payment for its benefit funded entirely by available insurance, which it plans to use as part of a payment to members of a putative class in a related securities class action settlement.
Plaintiffs in the derivative cases will also seek court-approved attorneys’ fees of up to $2,250,000, which the company expects to be fully paid by insurance. A final approval hearing is scheduled for March 18, 2026, and the stipulation states there is no admission of liability by the defendants or the company.
Inotiv, Inc. reported that executive Andrea Castetter, EVP, General Counsel & Secretary, received a grant of 10,000 employee stock options. The options have an exercise price of $0.5956 per share and were awarded as a non-qualified stock option grant. According to the filing, the options vest over three years on a 40% / 30% / 30% schedule beginning on the first anniversary of the January 15, 2026 grant date, contingent on continued employment. After the grant, Castetter beneficially owns 10,000 stock options directly, and the options are scheduled to expire on January 15, 2036.
Inotiv, Inc. reported that on December 31, 2025 it received a written notice from Nasdaq that its common stock is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share for 30 consecutive business days. The notice does not immediately affect the listing or trading of the common shares on Nasdaq.
Inotiv has 180 calendar days, until June 29, 2026, to regain compliance by having its stock close at or above $1.00 per share for at least 10 consecutive business days, subject to Nasdaq’s discretion to require a longer period. If it fails to do so, the company may be eligible for an additional 180-day grace period. Inotiv plans to monitor its share price and evaluate options, but there is no assurance it will regain or maintain compliance with Nasdaq listing requirements.
Inotiv, Inc. (NOTV) announced that it has issued a press release with select preliminary unaudited financial results for its fourth quarter and fiscal year ended September 30, 2025. These early figures are being shared ahead of final audited results to give the market an initial view of the company’s recent performance.
The company also disclosed that President and CEO Robert Leasure, Jr. will present at the Jefferies Global Healthcare Conference on November 18, 2025 at 6:00 a.m. Eastern time. A live webcast and replay of this presentation will be available through the Investors section of Inotiv’s website. The press release containing the preliminary results is furnished as Exhibit 99.1.
Inotiv (NOTV): Director Form 4 filing — Director R. Matthew Neff reported selling 2,000 shares of common stock on 11/03/2025 at a weighted average price of $1.2434 per share, with individual sale prices ranging from $1.2100 to $1.2900. The transaction was executed under a Rule 10b5-1 trading plan adopted on 02/13/2025 to cover tax obligations tied to prior equity award vesting. Following the sale, he beneficially owns 153,102 shares directly.
Inotiv, Inc. (NOTV) reported an insider transaction. Director R. Matthew Neff exercised a stock option and acquired 10,000 shares of common stock at $1.94 per share on 10/24/2025 (Transaction Code M). Following the transaction, he directly beneficially owns 155,102 common shares. The exercised derivative was a director stock option covering 10,000 underlying shares, which now has 0 remaining after the exercise; the option carried an expiration date of 10/27/2025.
R. Matthew Neff, a director of Inotiv, Inc. (Ticker: NOTV), reported the sale of 2,000 shares of common stock on 10/01/2025 at a weighted average price of $1.4289 per share. The filing shows 145,102 shares remain beneficially owned by Mr. Neff after the reported sale.
The filing states the sales were executed under a pre-existing Rule 10b5-1 trading plan adopted on February 13, 2025, and that the reported price is the weighted average of multiple sales that ranged from $1.4100 to $1.4650 per share. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Neff.